Literature DB >> 16487180

Specific polymorphisms of cytokine genes are associated with different risks to develop single-system or multi-system childhood Langerhans cell histiocytosis.

Paola De Filippi1, Carla Badulli, Mariaclara Cuccia, Annalisa De Silvestri, Ennia Dametto, Annamaria Pasi, Alberto Garaventa, Adalberto Brach del Prever, Alessandra Todesco, Antonino Trizzino, Cesare Danesino, Miryam Martinetti, Maurizio Aricò.   

Abstract

Cytokines and chemokines determine mobilisation of Langerhans cells and their dysregulation is implicated in the pathogenesis of Langerhans cell histiocytosis (LCH). Twenty point mutations of 12 different cytokine genes were studied in 41 Italian children, 15 with single-system (SS) and 26 with multi-system disease. The allele and genotype distributions of interleukin-4 (IL-4) and interferon-gamma (IFNgamma) were significantly different in patients vs. 140 controls (P = 0.007, and P = 0.018). Older children with single-system disease shared the 'anti-inflammatory profile' determined by the intermediate producer genotype IFNgamma +874A/T (P = 0.029) and the high-producer genotypes IL-4 -590C/T and T/T (P = 0.029). Our findings suggest that specific cytokine gene variants affect susceptibility to LCH and its clinical heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487180     DOI: 10.1111/j.1365-2141.2005.05922.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Langerhans cell histiocytosis with multisystem involvement in an infant: A case report.

Authors:  Lintao Bi; Butong Sun; Zhenxia Lu; Zhangzhen Shi; Dan Wang; Zhenxing Zhu
Journal:  Exp Ther Med       Date:  2015-03-30       Impact factor: 2.447

Review 2.  Intact IFN-γR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease.

Authors:  Willemijn T Quispel; Janine A Stegehuis-Kamp; Susy J Santos; Annelies van Wengen; Edward Dompeling; R Maarten Egeler; Esther van de Vosse; Astrid G S van Halteren
Journal:  J Clin Immunol       Date:  2013-11-20       Impact factor: 8.317

Review 3.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

4.  Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.

Authors:  Jennifer A West; Sharon L Olsen; Jenée M Mitchell; Ross E Priddle; Jennifer M Luke; Selma Olsson Akefeldt; Jan-Inge Henter; Christopher Turville; George Kannourakis
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

5.  Vulvar Langerhans cell histiocytosis: a case report.

Authors:  Nadia Khoummane; Cyriane Guimeya; Dominique Lipombi; François Gielen
Journal:  Pan Afr Med J       Date:  2014-06-06

Review 6.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

7.  Calvarial Langerhans cell histiocytosis in an Adult: Typical imaging findings in an atypical age group.

Authors:  Amjad Samara; Jordan Nepute; Hsiang-Chih Lu; Richard J Perrin; Rami W Eldaya
Journal:  Radiol Case Rep       Date:  2019-10-09

8.  Association between Pituitary Langerhans Cell Histiocytosis and Papillary Thyroid Carcinoma.

Authors:  Salvatore Guarino; Deborah Maria Giusti; Antonello Rubini; Pasqualino Favoriti; Cristina Fioravanti; Filippo Maria Di Matteo; Vito D'Andrea; Enrico De Antoni; Antonio Catania
Journal:  Clin Med Insights Case Rep       Date:  2013-12-09

9.  Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature.

Authors:  Norbert Neckel; Andrej Lissat; Arendt von Stackelberg; Nadine Thieme; Mohemed-Salim Doueiri; Birgit Spors; Benedicta Beck-Broichsitter; Max Heiland; Jan-Dirk Raguse
Journal:  Ther Adv Med Oncol       Date:  2019-10-19       Impact factor: 8.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.